Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 2/20 | 0.79 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 3/20 | 0.47 |
| ▸ | THRA | P10827 | 2/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9277642 | 0.84 | ALOX15 (0.56) | ALOX15SMN1; SMN2MAPTHPGDKMT2A | |
| SCHEMBL3610243 | 0.76 | MAPT (0.77) | ALOX15SMN1; SMN2MAPTHPGDTSHR | |
| SCHEMBL1103812 | 0.76 | SMN1; SMN2 (1.00) | ALOX15SMN1; SMN2MAPTHPGDTSHR | |
| SCHEMBL24938760 | 0.74 | ALOX15 (0.59) | ALOX15SMN1; SMN2MAPTHPGDTSHR | |
| SCHEMBL205825 | 0.74 | ALOX15 (0.69) | ALOX15SMN1; SMN2MAPTKMT2AAKR1B1 | |
| SCHEMBL5881463 | 0.74 | SMN1; SMN2 (0.64) | ALOX15SMN1; SMN2MAPTHPGDTSHR | |
| SCHEMBL30436701 | 0.73 | ALOX15 (0.50) | ALOX15SMN1; SMN2MAPTHPGDTSHR | |
| SCHEMBL20588938 | 0.73 | ALOX15 (0.62) | ALOX15SMN1; SMN2MAPTHPGDTSHR | |
| SCHEMBL3833719 | 0.72 | AKR1B1 (0.47) | ALOX15SMN1; SMN2MAPTHPGDTSHR | |
| SCHEMBL20588726 | 0.72 | LMNA (0.64) | ALOX15SMN1; SMN2MAPTHPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2646425-B1 | Indanyloxydihydrobenzofuranylacetic acids useful for the treatment of metabolic syndrome | BOEHRINGER INGELHEIM INT (DE) | 2015-06-10 | — | — | EP | disclosed |
| EP-2646425-B1 | Indanyloxydihydrobenzofuranylacetic acids useful for the treatment of metabolic syndrome | BOEHRINGER INGELHEIM INT (DE) | 2015-06-10 | — | — | EP | disclosed |
| EP-2646425-A1 | INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | Boehringer Ingelheim International GmbH (DE) | 2013-10-09 | — | — | EP | disclosed |
| US-20120302566-A1 | INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-11-29 | — | — | US | disclosed |
| US-20120302566-A1 | INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-11-29 | — | — | US | disclosed |
| US-20120302566-A1 | INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-11-29 | — | — | US | disclosed |
| WO-2012072691-A1 | INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | WO | disclosed |
| WO-2012072691-A1 | INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302566-A1 | INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | GPR119, INSR, GPR52 | ALOX15 1219/4885SMN1; SMN2 3965/4885MAPT 4526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.